These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33738175)

  • 41. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone-modifying Agents (BMAs) in Breast Cancer.
    Shapiro CL
    Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.
    Paterson AH; Shea-Budgell MA
    J Clin Med; 2013 Dec; 2(4):283-301. PubMed ID: 26237149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
    Eisen A; Somerfield MR; Accordino MK; Blanchette PS; Clemons MJ; Dhesy-Thind S; Dillmon MS; D'Oronzo S; Fletcher GG; Frank ES; Hallmeyer S; Makhoul I; Moy B; Thawer A; Wu JY; Van Poznak CH
    J Clin Oncol; 2022 Mar; 40(7):787-800. PubMed ID: 35041467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
    JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
    Lipton A; Fizazi K; Stopeck AT; Henry DH; Brown JE; Yardley DA; Richardson GE; Siena S; Maroto P; Clemens M; Bilynskyy B; Charu V; Beuzeboc P; Rader M; Viniegra M; Saad F; Ke C; Braun A; Jun S
    Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
    Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
    Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis.
    Miyashita H; Satoi S; Cruz C; Kim SM; Patel VG
    Support Care Cancer; 2022 Jan; 30(1):855-863. PubMed ID: 34392414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Side effects of bone-targeted therapies in advanced breast cancer.
    Domschke C; Schuetz F
    Breast Care (Basel); 2014 Oct; 9(5):332-6. PubMed ID: 25759613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Anderson K; Ismaila N; Flynn PJ; Halabi S; Jagannath S; Ogaily MS; Omel J; Raje N; Roodman GD; Yee GC; Kyle RA
    J Clin Oncol; 2018 Mar; 36(8):812-818. PubMed ID: 29341831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
    Palmieri C; Fullarton JR; Brown J
    Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
    Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H
    Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.